4-Week, Multi-Center, Randomized, Db-Blind, Placebo-Controlled, Dose-Ranging Study to Assess the Safety & Efficacy of Tenapanor for the T/t of IBS-C in Pts. 6 to < 12 Yrs. Old
Latest Information Update: 22 Jan 2025
At a glance
- Drugs Tenapanor (Primary)
- Indications Irritable bowel syndrome
- Focus Therapeutic Use
- Sponsors Ardelyx
Most Recent Events
- 19 Aug 2024 New trial record